To install click the Add extension button. That's it.
The source code for the WIKI 2 extension is being checked by specialists of the Mozilla Foundation, Google, and Apple. You could also do it yourself at any point in time.
How to transfigure the Wikipedia
Would you like Wikipedia to always look as professional and up-to-date? We have created a browser extension. It will enhance any encyclopedic page you visit with the magic of the WIKI 2 technology.
Try it — you can delete it anytime.
Install in 5 seconds
Yep, but later
4,5
Kelly Slayton
Congratulations on this excellent venture… what a great idea!
Alexander Grigorievskiy
I use WIKI 2 every day and almost forgot how the original Wikipedia looks like.
In June 2006, the developer Merck KGaA announced that the development of sarizotan was discontinued, after two sarizotan Phase III studies (PADDY I, PADDY II) failed to meet the primary efficacy endpoint and neither the Phase II findings nor the results from preclinical studies could be confirmed. No statistically significant difference of the primary target variable between sarizotan and placebo could be demonstrated.[8][9]
^Rabiner EA, Gunn RN, Wilkins MR, Sedman E, Grasby PM (September 2002). "Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11C]WAY-100635 and [11C]raclopride". Journal of Psychopharmacology. 16 (3): 195–9. doi:10.1177/026988110201600301. PMID12236624. S2CID12943982.
^Assié MB, Ravailhe V, Faucillon V, Newman-Tancredi A (October 2005). "Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain". The Journal of Pharmacology and Experimental Therapeutics. 315 (1): 265–72. doi:10.1124/jpet.105.087163. PMID15987834. S2CID9262233.
^Auclair AL, Galinier A, Besnard J, Newman-Tancredi A, Depoortère R (July 2007). "Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats". Psychopharmacology. 193 (1): 45–54. doi:10.1007/s00213-007-0762-7. PMID17393144. S2CID23379049.
^Bibbiani F, Oh JD, Chase TN (November 2001). "Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models". Neurology. 57 (10): 1829–34. doi:10.1212/wnl.57.10.1829. PMID11723272. S2CID24836560.
^Bartoszyk GD, Van Amsterdam C, Greiner HE, Rautenberg W, Russ H, Seyfried CA (February 2004). "Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile". Journal of Neural Transmission. 111 (2): 113–26. doi:10.1007/s00702-003-0094-7. PMID14767715. S2CID25419329.
^Grégoire L, Samadi P, Graham J, Bédard PJ, Bartoszyk GD, Di Paolo T (July 2009). "Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys". Parkinsonism & Related Disorders. 15 (6): 445–52. doi:10.1016/j.parkreldis.2008.11.001. PMID19196540.